Risk for Fournier Gangrene Identified With SGLT2 Inhibitor Use in Type 2 Diabetes
Clinicians should be aware of an increased risk for Fournier gangrene in patients with diabetes receiving sodium-glucose cotransporter 2 inhibitors.
Next post in Prevention
